Blood Clotting Factors Market By Product Type (Factors VII, Factor VIII, Factor IX, Factor X, Factor XIII, Von Willebrand Factor, Anti-Inhibitor Coagulant Complex, and Others), By Application (Haemophilia, Von Willebrand Disease, Surgery, and Other Bleeding Disorders), By Technology (Plasma-derived and Recombinant), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Blood Clotting Factors Market size was valued at USD 3,178.2 million in 2022 and is poised to grow at a CAGR of 6.9% from 2023-29. Blood clotting factors are proteins or enzymes that control bleeding. When a wound or blood vessel rupture occurs, a process known as blood clotting, also known as blood coagulation, causes blood to solidify into clots. In addition to limiting the entry of bacteria and viruses into the body, Clotting can prevent death from bleeding. The process of blood clotting, known as hemostasis, is regulated by a variety of elements collectively referred to as blood clotting factors. These deficiencies can result in blood clotting diseases such as hemophilia and von Willebrand disease (VWD). Over 20,000 men in the United States had hemophilia in 2017, according to the Centres for Disease Control and Prevention (CDC). The growing prevalence of traffic accidents is a primary factor driving market expansion. Increasing healthcare infrastructure development spending and an increase in the rates of cardiovascular diseases and blood disorders are two major factors driving market expansion. Some indirect variables that will generate attractive market growth prospects include rising personal disposable income and a rising need for laboratory automation. Increased R&D expenditure, a desire for preventative therapy, the development of innovative medications, and a rise in the prevalence of hemophilia are likely to accelerate the global expansion of the global blood clotting factor market. Yet, inadequate reimbursements and the high costs of homophilic medicines may limit market expansion. Improvements in healthcare infrastructure in emerging countries and the launch of biosimilar pharmaceuticals will present development prospects for the market. For example, on November 16th, 2017, the US Food and Drug Administration authorized Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A. They created antibodies called Factor VIII (FVIII) inhibitors. Additionally, on April 2, 2020, the U.S. Food and Drug Administration (FDA) authorized Sevenfact (coagulation factor VIIa [recombinant]) for the treatment and prevention of spontaneous bleeding episodes in patients aged 12 and older who have hemophilia A or B with inhibitors.

Blood Clotting Factors Market Key Developments:
  • In March 2019, Biotest AG gained regulatory clearance from 13 European countries for their Haematin SDH product offering for the treatment of Haemophilia A.

Blood Clotting Factors Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.9%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Blood Clotting Factors Market Dynamics

The approval of new medications is projected to drive the market growth of the market throughout the forecast period. For example, in January 2020, CSL Behring got permission from the Korea Ministry of Food and Drug Safety for Afstyla, a single-chain recombinant antihemophilic factor VIII treatment suggested for patients with Hemophilia A. In addition, Novo Nordisk gained marketing permission for Esperoct throughout Europe from the European Commission in June 2019. Esperoct is a brand name for the drug turoctocog alfa pegol, N8-GP, which is used in surgical operations in adolescents and adults with hemophilia A. (congenital factor VIII deficiency). Also, Novo Nordisk got Health Canada approval for Esperoct, which is recommended for the treatment of individuals with Hemophilia A, in July 2019. Moreover, rising initiatives and donations supporting patients diagnosed with Hemophilia are expected to propel the market growth over the forecast period.

Blood Clotting Factors Market Segmentation

By Product Type
  • Factor VII
  • Factor VIII
  • Factor IX
  • Factor X
  • Factor XIII
  • Von Willebrand Factor
  • Anti-Inhibitor Coagulant Complex
  • Others
By Application
  • Haemophilia
  • Von Willebrand disease (VWD)
  • Surgery
  • Other bleeding disorders
By Technology
  • Plasma-derived
  • Recombinant
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

AngioDynamics, Terumo Co., Johnson and Johnson, ECKOS Co., Bayer HealthCare LLC, Boston Scientific Co., Argon Medical Devices, Medtronic Plc, Teleflex Incorporated, Penumbra. are the top companies.

The major factors driving the market growth include the growing patient population base, R&D activities, and increasing focus on recombinant products by pharmaceutical companies. Emerging markets offer significant growth opportunities for the market.

The Asia pacific is expected to be the dominant regional segment of the market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1. Executive Summary
2. Global Blood Clotting Factors Market Introduction
2.1. Global Blood Clotting Factors Market – Taxonomy
2.2. Global Blood Clotting Factors Market – Definitions
2.2.1. By Product Type
2.2.2. By Application
2.2.3. By Technology
2.2.4. By Region
3. Global Blood Clotting Factors Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Blood Clotting Factors Market Dynamic Factors - Impact Analysis
3.6. Global Blood Clotting Factors Market – Competition Landscape
4. Global Blood Clotting Factors Market Analysis,2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Blood Clotting Factors Market, By Product Type, 2018–2022 and Forecast, 2023–2029 (Revenue, USD  Mn)
5.1. Factor VII
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Factor VIII
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Factor IX
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Factor X
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Factor XIII
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Von Willebrand Factor
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Anti-Inhibitor Coagulant Complex
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Others
5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
6. Global Blood Clotting Factors Market, By Application, 2018 – 2022 and Forecast, 2022 – 2027 (Revenue, USD Mn)
6.1. Haemophilia
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Von Willebrand disease (VWD)
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Surgery
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Other bleeding disorders
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Blood Clotting Factors Market, By Technology, 2018 – 2022 and Forecast, 2022 – 2027 (Revenue, USD Mn)
7.1. Plasma-derived
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Recombinant
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Blood Clotting Factors Market, By Distribution Channel, 2018 – 2022 and Forecast, 2022 – 2027 (Revenue, USD Mn)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Blood Clotting Factors Market Forecast, By Region, 2018–2022and Forecast, 2023–2029(Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Blood Clotting Factors Market - Opportunity Analysis Index, By Product Type, Application, Technology, and Region, 2023 - 2029
10. North America Blood Clotting Factors market analysis,2018–2022and Forecast, 2023–2029(Revenue, USD Mn)
10.1. Product Type Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Factor VII
10.1.2. Factor VIII
10.1.3. Factor IX
10.1.4. Factor X
10.1.5. Factor XIII
10.1.6. Von Willebrand Factor
10.1.7. Anti-Inhibitor Coagulant Complex
10.1.8. Others
10.2. Application Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Haemophilia
10.2.2. Von Willebrand disease (VWD)
10.2.3. Surgery
10.2.4. Other bleeding disorders
10.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Plasma-derived
10.3.2. Recombinant
10.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. USA
10.5.2. Canada
10.6. North America Blood Clotting Factors Market - Opportunity Analysis Index, By Product Type, Application, Technology, and Country, 2023 - 2029
10.7. North America Blood Clotting Factors Market Dynamics – Trends
11. Europe Blood Clotting Factors Market Analysis, 2018–2022and Forecast, 2023–2029(Revenue, USD Mn)
11.1. Product Type Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Factor VII
11.1.2. Factor VIII
11.1.3. Factor IX
11.1.4. Factor X
11.1.5. Factor XIII
11.1.6. Von Willebrand Factor
11.1.7. Anti-Inhibitor Coagulant Complex
11.1.8. Others
11.2. Application Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Haemophilia
11.2.2. Von Willebrand disease (VWD)
11.2.3. Surgery
11.2.4. Other bleeding disorders
11.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Plasma-derived
11.3.2. Recombinant
11.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis 2018–2022and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Blood Clotting Factors Market - Opportunity Analysis Index, By Product Type, Application, Technology, and Country, 2023 - 2029
11.7. Europe Blood Clotting Factors Market Dynamics – Trends
12. Asia-Pacific Blood Clotting Factors Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
12.1. Product Type Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Factor VII
12.1.2. Factor VIII
12.1.3. Factor IX
12.1.4. Factor X
12.1.5. Factor XIII
12.1.6. Von Willebrand Factor
12.1.7. Anti-Inhibitor Coagulant Complex
12.1.8. Others
12.2. Application Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Haemophilia
12.2.2. Von Willebrand disease (VWD)
12.2.3. Surgery
12.2.4. Other bleeding disorders
12.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Plasma-derived
12.3.2. Recombinant
12.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis2018–2022and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Blood Clotting Factors Market - Opportunity Analysis Index, By Product Type, Application, Technology, and Country,2023 - 2029
12.7. Asia-Pacific Blood Clotting Factors Market Dynamics – Trends
13. Latin America Blood Clotting Factors Market Analysis,2018 - 2022 and Forecast, 2023–2029(Revenue, USD Mn)
13.1. Product Type Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Factor VII
13.1.2. Factor VIII
13.1.3. Factor IX
13.1.4. Factor X
13.1.5. Factor XIII
13.1.6. Von Willebrand Factor
13.1.7. Anti-Inhibitor Coagulant Complex
13.1.8. Others
13.2. Application Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Haemophilia
13.2.2. Von Willebrand disease (VWD)
13.2.3. Surgery
13.2.4. Other bleeding disorders
13.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Plasma-derived
13.3.2. Recombinant
13.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis 2018–2022and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Rest of Latin America
13.6. Latin America Blood Clotting Factors Market - Opportunity Analysis Index, By Product Type, Application, Technology, and Country, 2023 - 2029
13.7. Latin America Blood Clotting Factors Market Dynamics – Trends
14. Middle East and Africa Blood Clotting Factors Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
14.1. Product Type Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Factor VII
14.1.2. Factor VIII
14.1.3. Factor IX
14.1.4. Factor X
14.1.5. Factor XIII
14.1.6. Von Willebrand Factor
14.1.7. Anti-Inhibitor Coagulant Complex
14.1.8. Others
14.2. Application Analysis 2018–2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.2.1. Haemophilia
14.2.2. Von Willebrand disease (VWD)
14.2.3. Surgery
14.2.4. Other bleeding disorders
14.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.3.1. Plasma-derived
14.3.2. Recombinant
14.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Blood Clotting Factors Market - Opportunity Analysis Index, By Product Type, Application, Technology, and Country, 2023 - 2029
14.7. MEA Blood Clotting Factors Market Dynamics – Trends
15. Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product Type& Service Testing Product Types, Key Developments, Strategies, and SWOT Analysis)
15.2.1. AngioDynamics
15.2.2. Terumo Co.
15.2.3. Johnson and Johnson
15.2.4. ECKOS Co.
15.2.5. Bayer HealthCare LLC
15.2.6. Boston Scientific Co.
15.2.7. Argon Medical Devices
15.2.8. Medtronic Plc
15.2.9. Teleflex Incorporated
15.2.10. Penumbra
16. Research Methodology
17. Key Assumptions and Acronyms
  • AngioDynamics
  • Terumo Co.
  • Johnson and Johnson
  • ECKOS Co.
  • Bayer HealthCare LLC
  • Boston Scientific Co.
  • Argon Medical Devices
  • Medtronic Plc
  • Teleflex Incorporated

Adjacent Markets